RUNX1T1 and acute myeloid leukemia: AML with RUNX1::RUNX1T1 fusion represents another paradigm of how a single cytogenetic abnormality of t(8;21)(q22;q22) suffices in delineating a distinct leukemia subtype, in terms of morphology, immunophenotype, association with recurrent cooperating mutations, and favorable clinical outcomes.